Fig. 3
From: The molecular basis of the anticancer effect of statins
Collection and processing of candidates to identify the repurposable drugs usable for the anticancer Synthetic Lethality approach. (a) The three-dimensional representation provides insight into the targeting of non-mutated genes in a Synthetic Lethality association with a deleted metastatic gene. The green triangles signify all the discerned drugs that target non-deleted genes in an SL pair with deleted metastatic genes, and are non-chemotherapeutic, totaling 1888. Among these, 230 candidates are repurposable (red dot). (b) The pie chart provides a visual representation of the distribution of the 1888 drugs we identified, grouped according to their status. Specifically, 44.8% of these drugs are already approved for cancer treatment, 43.0% are in clinical trial phase, while 12.2% encompass commercially available drugs that are used for non-cancer related treatments but have potential for repurposing in cancer therapy.
